Purpose: This study aimed to evaluate the associations between immune-related gene (FCRL3, NLRP3 and IL2) polymorphisms and the risk of head and neck cancer (HNC). Methods: Six polymorphisms of FCRL3, NLRP3 and IL2 were genotyped in 400 HNC cases and 400 controls using a MassARRAY platform. Results: rs11264799-T was a protective variant against HNC risk, while rs7528684-G, rs35829419-A and rs6822844-T were all risk alleles for HNC (p < 0.05). rs11264799-TT was correlated with reduced HNC risk, while rs7528684-GG and rs6822844-TG were associated with an elevated risk of disease (p < 0.05). Moreover, rs11264799 was correlated with a declining risk of HNC in three genetic models (p < 0.05). In contrast, rs7528684 exhibited an elevated risk of HNC in recessive and additive models; rs35829419 and rs6822844 were associated with an increased risk of disease in dominant and additive models (p < 0.05). Finally, an interaction was observed between the above SNPs and drinking (p < 0.05). Conclusion: The results expand our knowledge on immune-related gene polymorphisms in HNC and provide clues for further functional study on the pathogenesis of HNC.
第一作者单位:[1]Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp,Hosp 3, Shanxi Acad Med Sci,Dept Otolaryngol Head & Neck, Taiyuan 030032, Peoples R China[2]Huazhong Univ Sci & Technol, Dept Otolaryngol Head & Neck Surg, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Zhang Yuhao,Sun Dawei.Genetic Polymorphisms of FCRL3, NLRP3 and IL2 are Associated with the Risk of Head and Neck Cancer in a Chinese Population[J].PHARMACOGENOMICS & PERSONALIZED MEDICINE.2021,14:1047-1053.doi:10.2147/PGPM.S324750.
APA:
Zhang, Yuhao&Sun, Dawei.(2021).Genetic Polymorphisms of FCRL3, NLRP3 and IL2 are Associated with the Risk of Head and Neck Cancer in a Chinese Population.PHARMACOGENOMICS & PERSONALIZED MEDICINE,14,
MLA:
Zhang, Yuhao,et al."Genetic Polymorphisms of FCRL3, NLRP3 and IL2 are Associated with the Risk of Head and Neck Cancer in a Chinese Population".PHARMACOGENOMICS & PERSONALIZED MEDICINE 14.(2021):1047-1053